Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Sage Therapeutics Inc is a biotechnology business based in the US. Sage Therapeutics shares (SAGE) are listed on the NASDAQ and all prices are listed in US Dollars. Sage Therapeutics employs 298 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Long-term investors
Our top pick for
Beginners
Our top pick for
Active traders
| Latest market close | $39.66 |
|---|---|
| 52-week range | $36.05 - $88.51 |
| 50-day moving average | $40.75 |
| 200-day moving average | $51.30 |
| Wall St. target price | $74.55 |
| PE ratio | 3.5872 |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $11.06 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $39.66 from 2022-01-24
| 1 week (2022-01-14) | N/A |
|---|---|
| 1 month (2021-12-23) | -7.92% |
| 3 months (2021-10-21) | N/A |
| 6 months (2021-07-23) | -11.93% |
| 1 year (2021-01-25) | -56.16% |
|---|---|
| 2 years (2020-01-24) | -41.69% |
| 3 years (2019-01-25) | 132.02 |
| 5 years (2017-01-25) | 48.98 |
Valuing Sage Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Sage Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Sage Therapeutics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 4x. In other words, Sage Therapeutics shares trade at around 4x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Sage Therapeutics's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.74. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Sage Therapeutics's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Sage Therapeutics's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $642.9 million.
The EBITDA is a measure of a Sage Therapeutics's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $1.1 billion |
|---|---|
| Operating margin TTM | 57.32% |
| Gross profit TTM | $820.9 million |
| Return on assets TTM | 29.94% |
| Return on equity TTM | 51.48% |
| Profit margin | 57.61% |
| Book value | $31.20 |
| Market capitalisation | $2.3 billion |
TTM: trailing 12 months
We're not expecting Sage Therapeutics to pay a dividend over the next 12 months.
Over the last 12 months, Sage Therapeutics's shares have ranged in value from as little as $36.05 up to $88.51. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Sage Therapeutics's is 1.7466. This would suggest that Sage Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Sage Therapeutics, Inc. , a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive steroid, which is in Phase III clinical trials for treating PPD, major depressive disorders, bipolar depression, and generalized anxiety disorders; and SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases. In addition, its product pipeline comprises SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which has completed Phase I clinical trial for the treatment of depression, Huntington's disease, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. Sage Therapeutics, Inc. has a strategic collaboration with Shionogi & Co.
Melania Trump launched an NFT platform — you can buy an image of her eyes.
Read our expert analysis on Vigorus and how the token will perform in the future.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Starting Jan. 18, every household can order up to four free at-home COVID-19 tests. But you’ll have to wait for them.
While there are no known plans to expand the acceptance of Doge to its cars, customers can already buy a Tesla with Bitcoin.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Donut earns up to 10% APY, but you must have an iOS device.
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.
Buffett’s Berkshire Hathaway may now be on its way to becoming the next trillion-dollar company.
